marketcaparena
Search

    ABT

    ABBOTT LABORATORIES

    Company overview

    Market capitalization
    $175.89B
    Employees
    122,000
    Latest publication
    2026-09-29
    About ABBOTT LABORATORIES

    Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue12,593,000,000USD11,164,000,000USD11,459,000,000USD11,369,000,000USD11,142,000,000USD10,358,000,000USD10,974,000,000USD10,635,000,000USD
    Cost Of Revenue5,325,000,000USD4,890,000,000USD4,922,000,000USD5,031,000,000USD4,854,000,000USD4,914,000,000USD5,376,000,000USD5,209,000,000USD
    Gross Profit7,268,000,000USD6,274,000,000USD6,537,000,000USD6,338,000,000USD6,288,000,000USD5,444,000,000USD5,598,000,000USD5,426,000,000USD
    Research Development892,000,000USD767,000,000USD735,000,000USD785,000,000USD732,000,000USD703,000,000USD728,000,000USD713,000,000USD
    Selling General Administrative4,025,000,000USD3,740,000,000USD3,129,000,000USD3,051,000,000USD3,090,000,000USD3,061,000,000USD2,907,000,000USD2,895,000,000USD
    Other Operating Expenses658,000,000USD———————
    Total Operating Expenses5,575,000,000USD4,929,000,000USD4,286,000,000USD4,308,000,000USD4,236,000,000USD3,756,000,000USD3,608,000,000USD3,608,000,000USD
    Operating Income1,693,000,000USD1,345,000,000USD2,251,000,000USD2,057,000,000USD2,052,000,000USD1,688,000,000USD1,990,000,000USD1,818,000,000USD
    Total Other Income Expense Net-169,000,000USD104,000,000USD107,000,000USD123,000,000USD98,000,000USD90,000,000USD40,000,000USD122,000,000USD
    Interest Income52,000,000USD106,000,000USD27,000,000USD77,000,000USD39,000,000USD82,000,000USD91,000,000USD91,000,000USD
    Interest Expense351,000,000USD174,000,000USD120,000,000USD44,000,000USD121,000,000USD134,000,000USD152,000,000USD166,000,000USD
    Income Before Tax1,524,000,000USD1,449,000,000USD2,358,000,000USD2,180,000,000USD2,150,000,000USD1,778,000,000USD2,030,000,000USD1,940,000,000USD
    Income Tax Expense596,000,000USD372,000,000USD582,000,000USD536,000,000USD371,000,000USD453,000,000USD-7,199,000,000USD294,000,000USD
    Net Income928,000,000USD1,077,000,000USD1,776,000,000USD1,644,000,000USD1,779,000,000USD1,325,000,000USD9,229,000,000USD1,646,000,000USD
    Net Income Applicable To Common Shares—1,100,000,000USD1,776,000,000USD1,644,000,000USD1,779,000,000USD1,325,000,000USD9,229,000,000USD—
    Unclassified Operating Expenses——422,000,000USD472,000,000USD414,000,000USD———
    Net Interest Income——-42,000,000USD-44,000,000USD-50,000,000USD-49,000,000USD-45,000,000USD-51,000,000USD
    Tax Provision——582,000,000USD536,000,000USD371,000,000USD453,000,000USD-7,199,000,000USD294,000,000USD
    Net Income From Continuing Ops——1,776,000,000USD1,644,000,000USD1,779,000,000USD1,325,000,000USD9,229,000,000USD1,646,000,000USD
    Ebit——2,400,000,000USD2,301,000,000USD2,271,000,000USD1,912,000,000USD2,182,000,000USD2,106,000,000USD
    Ebitda——2,822,000,000USD3,092,000,000USD3,048,000,000USD2,668,000,000USD2,989,000,000USD2,907,000,000USD
    Depreciation And Amortization——422,000,000USD791,000,000USD777,000,000USD756,000,000USD807,000,000USD801,000,000USD
    Reconciled Depreciation——792,000,000USD791,000,000USD777,000,000USD756,000,000USD807,000,000USD801,000,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue44,328,000,000USD41,950,000,000USD40,109,000,000USD43,653,000,000USD43,075,000,000USD34,608,000,000USD31,904,000,000USD30,578,000,000USD
    Cost Of Revenue19,721,000,000USD20,625,000,000USD20,072,000,000USD21,330,000,000USD19,861,000,000USD17,231,000,000USD15,211,000,000USD14,755,000,000USD
    Gross Profit24,607,000,000USD21,325,000,000USD20,037,000,000USD22,323,000,000USD23,214,000,000USD17,377,000,000USD16,693,000,000USD15,823,000,000USD
    Research Development2,955,000,000USD2,823,000,000USD2,719,000,000USD2,852,000,000USD2,738,000,000USD2,418,000,000USD2,408,000,000USD2,288,000,000USD
    Selling General Administrative12,378,000,000USD11,697,000,000USD11,198,000,000USD11,012,000,000USD11,324,000,000USD9,696,000,000USD9,765,000,000USD9,744,000,000USD
    Unclassified Operating Expenses1,253,000,000USD—-315,000,000USD—————
    Total Operating Expenses16,586,000,000USD14,474,000,000USD13,602,000,000USD13,961,000,000USD14,014,000,000USD12,086,000,000USD12,102,000,000USD11,979,000,000USD
    Operating Income8,048,000,000USD6,825,000,000USD6,435,000,000USD8,362,000,000USD9,200,000,000USD5,291,000,000USD4,591,000,000USD3,844,000,000USD
    Interest Income135,000,000USD344,000,000USD384,000,000USD377,000,000USD491,000,000USD492,000,000USD94,000,000USD105,000,000USD
    Interest Expense341,000,000USD603,000,000USD698,000,000USD315,000,000USD410,000,000USD708,000,000USD818,000,000USD729,000,000USD
    Net Interest Income-185,000,000USD-215,000,000USD-248,000,000USD-375,000,000USD-490,000,000USD-500,000,000USD-576,000,000USD-721,000,000USD
    Income Before Tax8,466,000,000USD7,013,000,000USD6,664,000,000USD8,306,000,000USD8,211,000,000USD4,968,000,000USD4,077,000,000USD2,873,000,000USD
    Income Tax Expense1,942,000,000USD-6,389,000,000USD941,000,000USD1,373,000,000USD1,140,000,000USD497,000,000USD390,000,000USD539,000,000USD
    Tax Provision1,942,000,000USD-6,389,000,000USD1,027,000,000USD1,373,000,000USD1,140,000,000USD497,000,000USD390,000,000USD539,000,000USD
    Net Income6,524,000,000USD13,402,000,000USD5,723,000,000USD6,933,000,000USD7,071,000,000USD4,495,000,000USD3,687,000,000USD2,368,000,000USD
    Net Income From Continuing Ops6,524,000,000USD13,402,000,000USD5,162,000,000USD6,933,000,000USD7,071,000,000USD4,471,000,000USD3,687,000,000USD2,334,000,000USD
    Ebit8,807,000,000USD7,616,000,000USD7,362,000,000USD8,621,000,000USD8,621,000,000USD5,676,000,000USD4,895,000,000USD3,602,000,000USD
    Ebitda11,553,000,000USD10,834,000,000USD10,605,000,000USD11,888,000,000USD12,159,000,000USD9,003,000,000USD7,909,000,000USD6,880,000,000USD
    Depreciation And Amortization2,746,000,000USD3,218,000,000USD3,243,000,000USD3,267,000,000USD3,538,000,000USD3,327,000,000USD3,014,000,000USD3,278,000,000USD
    Reconciled Depreciation3,116,000,000USD3,218,000,000USD3,237,000,000USD2,013,000,000USD2,047,000,000USD3,327,000,000USD3,014,000,000USD3,278,000,000USD
    Total Other Income Expense Net418,000,000USD188,000,000USD229,000,000USD-56,000,000USD-989,000,000USD-323,000,000USD-514,000,000USD-971,000,000USD
    Net Income Applicable To Common Shares6,524,000,000USD13,402,000,000USD5,723,000,000USD6,933,000,000USD7,071,000,000USD4,495,000,000USD3,687,000,000USD2,353,000,000USD
    Non Operating Income Net Other———502,000,000USD319,000,000USD157,000,000USD215,000,000USD49,000,000USD
    Minority Interest—————219,000,000USD213,000,000USD198,000,000USD
    Discontinued Operations—————24,000,000USD24,000,000USD34,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets109,215,000,000USD110,429,000,000USD86,713,000,000USD84,181,000,000USD83,999,000,000USD81,448,000,000USD81,414,000,000USD74,356,000,000USD
    Cash And Equivalents5,104,000,000USD6,803,000,000USD8,522,000,000USD7,511,000,000USD6,951,000,000USD6,532,000,000USD7,616,000,000USD7,558,000,000USD
    Cash And Short Term Investments5,603,000,000USD7,295,000,000USD8,939,000,000USD7,733,000,000USD7,282,000,000USD6,844,000,000USD7,967,000,000USD7,788,000,000USD
    Short Term Investments499,000,000USD492,000,000USD417,000,000USD222,000,000USD331,000,000USD312,000,000USD351,000,000USD230,000,000USD
    Long Term Investments1,111,000,000USD1,090,000,000USD918,000,000USD951,000,000USD958,000,000USD907,000,000USD886,000,000USD912,000,000USD
    Total Current Assets24,517,000,000USD25,508,000,000USD25,996,000,000USD24,839,000,000USD24,468,000,000USD23,153,000,000USD23,656,000,000USD23,802,000,000USD
    Total Liabilities57,453,000,000USD57,728,000,000USD——————
    Total Current Liabilities17,814,000,000USD18,377,000,000USD16,496,000,000USD14,582,000,000USD13,439,000,000USD13,004,000,000USD14,157,000,000USD14,902,000,000USD
    Total Stockholder Equity51,110,000,000USD52,061,000,000USD52,130,000,000USD50,954,000,000USD50,565,000,000USD48,811,000,000USD47,664,000,000USD39,796,000,000USD
    Total Equity Including Noncontrolling Interest51,762,000,000USD52,701,000,000USD——————
    Short Long Term Debt3,005,000,000USD4,409,000,000USD3,033,000,000USD1,345,000,000USD507,000,000USD506,000,000USD1,500,000,000USD2,154,000,000USD
    Long Term Debt29,603,000,000USD29,638,000,000USD9,896,000,000USD11,596,000,000USD12,930,000,000USD12,736,000,000USD12,625,000,000USD12,825,000,000USD
    Net Receivables8,599,000,000USD8,210,000,000USD7,929,000,000USD8,138,000,000USD7,972,000,000USD7,327,000,000USD6,925,000,000USD7,051,000,000USD
    Inventory7,315,000,000USD6,989,000,000USD6,488,000,000USD6,708,000,000USD6,954,000,000USD6,639,000,000USD6,194,000,000USD6,813,000,000USD
    Property Plant Equipment Net12,812,000,000USD12,377,000,000USD12,942,000,000USD11,504,000,000USD11,395,000,000USD10,932,000,000USD11,733,000,000USD10,621,000,000USD
    Goodwill35,244,000,000USD35,221,000,000USD——————
    Intangible Assets17,211,000,000USD17,875,000,000USD5,526,000,000USD5,598,000,000USD5,920,000,000USD6,261,000,000USD6,647,000,000USD7,352,000,000USD
    Accounts Payable4,794,000,000USD4,679,000,000USD4,240,000,000USD4,123,000,000USD4,306,000,000USD4,214,000,000USD4,195,000,000USD4,034,000,000USD
    Common Stock25,495,000,000USD25,352,000,000USD25,527,000,000USD25,412,000,000USD25,284,000,000USD25,125,000,000USD25,153,000,000USD25,020,000,000USD
    Retained Earnings49,794,000,000USD49,956,000,000USD49,781,000,000USD49,103,000,000USD48,467,000,000USD47,715,000,000USD47,261,000,000USD39,056,000,000USD
    Accumulated Other Comprehensive Income-6,212,000,000USD-6,312,000,000USD-6,001,000,000USD-6,684,000,000USD-6,576,000,000USD-7,417,000,000USD-7,906,000,000USD-7,804,000,000USD
    Other Current Assets——2,640,000,000USD2,260,000,000USD2,260,000,000USD2,343,000,000USD2,570,000,000USD2,150,000,000USD
    Total Liab——33,942,000,000USD32,917,000,000USD33,170,000,000USD32,384,000,000USD33,513,000,000USD34,328,000,000USD
    Other Current Liab——8,378,000,000USD8,645,000,000USD8,236,000,000USD7,799,000,000USD7,614,000,000USD8,001,000,000USD
    Capital Stock——25,527,000,000USD25,412,000,000USD25,284,000,000USD25,125,000,000USD25,153,000,000USD25,020,000,000USD
    Good Will——24,035,000,000USD23,971,000,000USD23,952,000,000USD23,359,000,000USD23,108,000,000USD23,658,000,000USD
    Other Assets——18,422,000,000USD4,000,000USD17,306,000,000USD-12,486,000,000USD16,459,000,000USD8,011,000,000USD
    Cash——8,522,000,000USD7,511,000,000USD6,951,000,000USD6,532,000,000USD7,616,000,000USD7,558,000,000USD
    Net Debt——6,545,000,000USD5,430,000,000USD6,486,000,000USD6,710,000,000USD7,659,000,000USD7,421,000,000USD
    Short Term Debt——3,309,000,000USD1,345,000,000USD507,000,000USD506,000,000USD1,754,000,000USD2,154,000,000USD
    Short Long Term Debt Total——15,067,000,000USD12,941,000,000USD13,437,000,000USD13,242,000,000USD15,275,000,000USD14,979,000,000USD
    Property Plant Equipment Gross——25,222,000,000USD24,816,000,000USD24,472,000,000USD23,418,000,000USD22,740,000,000USD22,857,000,000USD
    Common Stock Shares Outstanding——1,747,000,000shares1,749,000,000shares1,751,000,000shares1,747,220,000shares1,746,000,000shares1,748,000,000shares
    Non Current Assets Total——60,717,000,000USD59,342,000,000USD59,531,000,000USD58,295,000,000USD57,758,000,000USD50,554,000,000USD
    Non Current Liabilities Total——17,446,000,000USD18,335,000,000USD19,731,000,000USD19,380,000,000USD19,356,000,000USD19,426,000,000USD
    Non Current Liabilities Other——2,538,000,000USD6,739,000,000USD6,801,000,000USD6,644,000,000USD3,443,000,000USD6,601,000,000USD
    Non Currrent Assets Other——17,296,000,000USD17,318,000,000USD17,306,000,000USD16,836,000,000USD15,384,000,000USD8,011,000,000USD
    Net Working Capital——9,500,000,000USD10,257,000,000USD11,029,000,000USD10,149,000,000USD9,499,000,000USD8,900,000,000USD
    Unclassified Non Current Assets——-18,422,000,000USD—-17,306,000,000USD—-16,459,000,000USD-8,011,000,000USD
    Unclassified Current Liabilities——-2,464,000,000USD-876,000,000USD——-906,000,000USD-1,441,000,000USD
    Unclassified Non Current Liabilities——5,012,000,000USD———3,288,000,000USD—
    Unclassified Equity——-42,704,000,000USD-42,289,000,000USD-41,894,000,000USD-41,737,000,000USD-41,997,000,000USD-41,496,000,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets86,713,000,000USD81,414,000,000USD73,214,000,000USD74,438,000,000USD75,196,000,000USD72,548,000,000USD67,887,000,000USD67,173,000,000USD
    Intangible Assets5,526,000,000USD6,647,000,000USD8,815,000,000USD10,454,000,000USD12,739,000,000USD14,784,000,000USD17,025,000,000USD18,942,000,000USD
    Other Current Assets2,640,000,000USD2,570,000,000USD2,256,000,000USD2,663,000,000USD2,346,000,000USD1,867,000,000USD1,786,000,000USD1,568,000,000USD
    Total Liab33,942,000,000USD33,513,000,000USD34,387,000,000USD37,533,000,000USD39,172,000,000USD39,545,000,000USD36,586,000,000USD36,451,000,000USD
    Total Stockholder Equity52,130,000,000USD47,664,000,000USD38,603,000,000USD36,686,000,000USD35,802,000,000USD32,784,000,000USD31,088,000,000USD30,524,000,000USD
    Other Current Liab8,378,000,000USD7,614,000,000USD7,729,000,000USD8,058,000,000USD7,392,000,000USD7,138,000,000USD5,702,000,000USD5,525,000,000USD
    Common Stock25,527,000,000USD25,153,000,000USD24,869,000,000USD24,709,000,000USD24,470,000,000USD24,145,000,000USD23,853,000,000USD23,512,000,000USD
    Capital Stock25,527,000,000USD25,153,000,000USD24,869,000,000USD24,709,000,000USD24,470,000,000USD24,145,000,000USD23,853,000,000USD23,512,000,000USD
    Retained Earnings49,781,000,000USD47,261,000,000USD37,554,000,000USD35,257,000,000USD31,528,000,000USD27,627,000,000USD25,847,000,000USD24,560,000,000USD
    Good Will24,035,000,000USD23,108,000,000USD23,679,000,000USD22,799,000,000USD23,231,000,000USD23,744,000,000USD23,195,000,000USD23,254,000,000USD
    Other Assets17,296,000,000USD15,384,000,000USD5,975,000,000USD4,917,000,000USD4,059,000,000USD2,784,000,000USD2,443,000,000USD2,192,000,000USD
    Cash8,522,000,000USD7,616,000,000USD6,896,000,000USD9,882,000,000USD9,799,000,000USD6,838,000,000USD3,860,000,000USD3,844,000,000USD
    Cash And Equivalents8,522,000,000USD7,616,000,000USD6,896,000,000USD9,882,000,000USD9,799,000,000USD6,838,000,000USD3,860,000,000USD3,844,000,000USD
    Cash And Short Term Investments8,939,000,000USD7,967,000,000USD7,279,000,000USD10,170,000,000USD10,249,000,000USD7,148,000,000USD4,140,000,000USD4,086,000,000USD
    Total Current Assets25,996,000,000USD23,656,000,000USD22,670,000,000USD25,224,000,000USD24,239,000,000USD20,441,000,000USD15,667,000,000USD14,632,000,000USD
    Total Current Liabilities16,496,000,000USD14,157,000,000USD13,841,000,000USD15,489,000,000USD13,105,000,000USD11,907,000,000USD10,863,000,000USD9,012,000,000USD
    Net Debt6,545,000,000USD7,659,000,000USD8,977,000,000USD8,064,000,000USD9,452,000,000USD13,052,000,000USD15,239,000,000USD15,722,000,000USD
    Short Term Debt3,309,000,000USD1,754,000,000USD1,325,000,000USD2,481,000,000USD999,000,000USD461,000,000USD1,683,000,000USD207,000,000USD
    Short Long Term Debt3,033,000,000USD1,500,000,000USD1,080,000,000USD2,251,000,000USD754,000,000USD220,000,000USD1,478,000,000USD207,000,000USD
    Short Long Term Debt Total15,067,000,000USD15,275,000,000USD15,873,000,000USD17,946,000,000USD19,251,000,000USD19,890,000,000USD19,099,000,000USD19,566,000,000USD
    Long Term Debt9,896,000,000USD12,625,000,000USD13,599,000,000USD14,522,000,000USD17,296,000,000USD18,527,000,000USD16,661,000,000USD19,359,000,000USD
    Long Term Investments918,000,000USD886,000,000USD799,000,000USD766,000,000USD816,000,000USD821,000,000USD883,000,000USD897,000,000USD
    Short Term Investments417,000,000USD351,000,000USD383,000,000USD288,000,000USD450,000,000USD310,000,000USD280,000,000USD242,000,000USD
    Net Receivables7,929,000,000USD6,925,000,000USD6,565,000,000USD6,218,000,000USD6,487,000,000USD6,414,000,000USD5,425,000,000USD5,182,000,000USD
    Inventory6,488,000,000USD6,194,000,000USD6,570,000,000USD6,173,000,000USD5,157,000,000USD5,012,000,000USD4,316,000,000USD3,796,000,000USD
    Accounts Payable4,240,000,000USD4,195,000,000USD4,295,000,000USD4,607,000,000USD4,408,000,000USD3,946,000,000USD3,252,000,000USD2,975,000,000USD
    Property Plant Equipment Net12,942,000,000USD11,733,000,000USD11,276,000,000USD10,278,000,000USD10,112,000,000USD10,130,000,000USD8,972,000,000USD7,563,000,000USD
    Property Plant Equipment Gross25,222,000,000USD22,740,000,000USD21,933,000,000USD20,212,000,000USD19,364,000,000USD9,029,000,000USD8,038,000,000USD7,563,000,000USD
    Accumulated Other Comprehensive Income-6,001,000,000USD-7,906,000,000USD-7,839,000,000USD-8,051,000,000USD-8,374,000,000USD-8,946,000,000USD-8,465,000,000USD-7,586,000,000USD
    Common Stock Shares Outstanding1,747,000,000shares1,748,000,000shares1,749,000,000shares1,764,000,000shares1,789,000,000shares1,786,000,000shares1,781,000,000shares1,770,000,000shares
    Non Current Assets Total60,717,000,000USD57,758,000,000USD50,544,000,000USD49,214,000,000USD50,957,000,000USD52,107,000,000USD52,220,000,000USD52,541,000,000USD
    Non Current Liabilities Total17,446,000,000USD19,356,000,000USD20,546,000,000USD22,044,000,000USD26,067,000,000USD27,638,000,000USD25,723,000,000USD27,439,000,000USD
    Non Current Liabilities Other2,538,000,000USD3,443,000,000USD3,466,000,000USD3,804,000,000USD3,685,000,000USD3,684,000,000USD3,944,000,000USD3,984,000,000USD
    Non Currrent Assets Other17,296,000,000USD15,384,000,000USD5,975,000,000USD4,917,000,000USD3,972,000,000USD2,418,000,000USD2,097,000,000USD1,885,000,000USD
    Net Working Capital9,500,000,000USD9,499,000,000USD8,829,000,000USD9,735,000,000USD11,134,000,000USD8,534,000,000USD4,804,000,000USD5,620,000,000USD
    Unclassified Non Current Assets-17,296,000,000USD-15,384,000,000USD-5,975,000,000USD-4,917,000,000USD-3,972,000,000USD-2,574,000,000USD-2,395,000,000USD-2,192,000,000USD
    Unclassified Current Liabilities-2,464,000,000USD-906,000,000USD-762,000,000USD-1,908,000,000USD-448,000,000USD142,000,000USD-1,252,000,000USD-207,000,000USD
    Unclassified Non Current Liabilities5,012,000,000USD3,288,000,000USD3,481,000,000USD-2,861,000,000USD-2,729,000,000USD-2,782,000,000USD-3,189,000,000USD-3,984,000,000USD
    Unclassified Equity-42,704,000,000USD-41,997,000,000USD-40,850,000,000USD-39,938,000,000USD-24,470,000,000USD-24,145,000,000USD-23,853,000,000USD-23,512,000,000USD
    Current Deferred Revenue——174,000,000USD————305,000,000USD
    Other Liab———6,579,000,000USD7,815,000,000USD8,209,000,000USD8,307,000,000USD8,080,000,000USD
    Accumulated Depreciation———-11,050,000,000USD-10,405,000,000USD-9,764,000,000USD-8,761,000,000USD-8,143,000,000USD
    Net Tangible Assets———10,955,000,000USD-2,189,000,000USD3,367,000,000USD-70,000,000USD-11,672,000,000USD
    Treasury Stock————-11,822,000,000USD-10,042,000,000USD-10,147,000,000USD-9,962,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Net Income2,005,000,000USD
    Depreciation783,000,000USD
    Stock Based Compensation485,000,000USD
    Other Non Cash Items1,080,000,000USD
    Unclassified Operating Cash Flow0USD
    Change In Working Capital-550,000,000USD
    Operating Cash Flow3,803,000,000USD
    Capital Expenditures-896,000,000USD
    Net Investments-187,000,000USD
    Unclassified Investing Cash Flow-19,914,000,000USD
    Investing Cash Flow-20,997,000,000USD
    Net Debt Issuance17,101,000,000USD
    Net Common Stock Issuance-1,106,000,000USD
    Common Dividends Paid-2,200,000,000USD
    Financing Cash Flow13,795,000,000USD
    Effect Of Forex Changes On Cash-19,000,000USD
    Change In Cash-3,418,000,000USD
    End Cash Flow5,104,000,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Depreciation803,000,000USD792,000,000USD791,000,000USD777,000,000USD756,000,000USD807,000,000USD801,000,000USD805,000,000USD
    Stock Based Compensation317,000,000USD113,000,000USD120,000,000USD142,000,000USD289,000,000USD111,000,000USD117,000,000USD141,000,000USD
    Change To Account Receivables-42,000,000USD222,000,000USD-202,000,000USD-410,000,000USD-262,000,000USD-158,000,000USD-57,000,000USD-325,000,000USD
    Change To Inventory-420,000,000USD234,000,000USD213,000,000USD3,000,000USD-255,000,000USD235,000,000USD220,000,000USD-103,000,000USD
    Change In Working Capital-462,000,000USD569,000,000USD232,000,000USD-651,000,000USD-953,000,000USD-8,391,000,000USD163,000,000USD-428,000,000USD
    Operating Cash Flow1,315,000,000USD———————
    Capital Expenditures-399,000,000USD-689,000,000USD-496,000,000USD-502,000,000USD-484,000,000USD-720,000,000USD-556,000,000USD-533,000,000USD
    Other Investing Activities-34,000,000USD———————
    Unclassified Investing Cash Flow-19,891,000,000USD-50,000,000USD492,000,000USD530,000,000USD478,000,000USD716,000,000USD554,000,000USD531,000,000USD
    Investing Cash Flow-20,324,000,000USD———————
    Net Debt Issuance18,475,000,000USD———————
    Net Common Stock Issuance-180,000,000USD———————
    Common Dividends Paid-1,098,000,000USD———————
    Unclassified Financing Cash Flow116,000,000USD87,000,000USD—35,000,000USD———160,000,000USD
    Financing Cash Flow17,313,000,000USD———————
    Effect Of Forex Changes On Cash-23,000,000USD———————
    Change In Cash-1,719,000,000USD1,011,000,000USD560,000,000USD419,000,000USD-1,084,000,000USD58,000,000USD571,000,000USD703,000,000USD
    End Cash Flow6,803,000,000USD———————
    Net Income—1,776,000,000USD1,644,000,000USD1,779,000,000USD1,325,000,000USD9,229,000,000USD1,646,000,000USD1,302,000,000USD
    Other Non Cash Items—65,000,000USD221,000,000USD-244,000,000USD-436,000,000USD1,112,000,000USD-22,000,000USD140,000,000USD
    Total Cash From Operating Activities—3,315,000,000USD2,787,000,000USD2,047,000,000USD1,417,000,000USD2,868,000,000USD2,705,000,000USD1,960,000,000USD
    Free Cash Flow—2,626,000,000USD2,291,000,000USD1,545,000,000USD933,000,000USD2,148,000,000USD2,149,000,000USD1,427,000,000USD
    Investments—-210,000,000USD-457,000,000USD-582,000,000USD-470,000,000USD-866,000,000USD-594,000,000USD-453,000,000USD
    Total Cashflows From Investing Activities—-913,000,000USD-457,000,000USD-582,000,000USD-470,000,000USD-866,000,000USD-594,000,000USD-453,000,000USD
    Net Borrowings—-70,000,000USD-493,000,000USD-15,000,000USD-1,036,000,000USD-613,000,000USD43,000,000USD—
    Total Cash From Financing Activities—-1,397,000,000USD-1,760,000,000USD-1,097,000,000USD-2,055,000,000USD-1,861,000,000USD-1,576,000,000USD-791,000,000USD
    Dividends Paid—-1,030,000,000USD-1,031,000,000USD-1,029,000,000USD-1,026,000,000USD-958,000,000USD-960,000,000USD-961,000,000USD
    Sale Purchase Of Stock—-302,000,000USD-305,000,000USD-6,000,000USD-280,000,000USD-315,000,000USD-751,000,000USD-3,000,000USD
    Begin Period Cash Flow—7,511,000,000USD6,951,000,000USD6,532,000,000USD7,616,000,000USD7,558,000,000USD6,987,000,000USD6,284,000,000USD
    End Period Cash Flow—8,522,000,000USD7,511,000,000USD6,951,000,000USD6,532,000,000USD7,616,000,000USD7,558,000,000USD6,987,000,000USD
    Other Cashflows From Investing Activities—36,000,000USD4,000,000USD-28,000,000USD6,000,000USD4,000,000USD2,000,000USD2,000,000USD
    Other Cashflows From Financing Activities—-82,000,000USD69,000,000USD-82,000,000USD287,000,000USD25,000,000USD92,000,000USD13,000,000USD
    Unclassified Operating Cash Flow——-221,000,000USD244,000,000USD436,000,000USD———
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income6,524,000,000USD13,402,000,000USD5,723,000,000USD6,933,000,000USD7,071,000,000USD4,495,000,000USD3,687,000,000USD2,368,000,000USD
    Depreciation3,116,000,000USD3,218,000,000USD3,243,000,000USD3,267,000,000USD3,538,000,000USD3,327,000,000USD3,014,000,000USD3,278,000,000USD
    Stock Based Compensation664,000,000USD673,000,000USD644,000,000USD685,000,000USD640,000,000USD546,000,000USD519,000,000USD477,000,000USD
    Other Non Cash Items65,000,000USD482,000,000USD126,000,000USD215,000,000USD55,000,000USD425,000,000USD247,000,000USD32,000,000USD
    Change To Account Receivables-652,000,000USD-691,000,000USD-356,000,000USD-68,000,000USD-383,000,000USD-924,000,000USD-275,000,000USD-190,000,000USD
    Change To Inventory195,000,000USD-58,000,000USD-232,000,000USD-1,413,000,000USD-456,000,000USD-493,000,000USD-593,000,000USD-514,000,000USD
    Change In Working Capital-803,000,000USD-9,217,000,000USD-2,475,000,000USD-1,519,000,000USD-771,000,000USD-892,000,000USD-1,331,000,000USD-148,000,000USD
    Total Cash From Operating Activities9,566,000,000USD8,558,000,000USD7,261,000,000USD9,581,000,000USD10,533,000,000USD7,901,000,000USD6,136,000,000USD6,300,000,000USD
    Capital Expenditures-2,171,000,000USD-2,207,000,000USD-2,202,000,000USD-1,777,000,000USD-1,885,000,000USD-2,177,000,000USD-1,638,000,000USD-1,394,000,000USD
    Free Cash Flow7,395,000,000USD6,351,000,000USD5,059,000,000USD7,804,000,000USD8,648,000,000USD5,724,000,000USD4,498,000,000USD4,906,000,000USD
    Investments-164,000,000USD-2,338,000,000USD-2,941,000,000USD-33,000,000USD-96,000,000USD-73,000,000USD-82,000,000USD-58,000,000USD
    Total Cashflows From Investing Activities-2,422,000,000USD-2,338,000,000USD-3,133,000,000USD-1,740,000,000USD-2,008,000,000USD-2,215,000,000USD-1,815,000,000USD-1,356,000,000USD
    Net Borrowings-1,614,000,000USD-537,000,000USD-2,475,000,000USD47,000,000USD-248,000,000USD-50,000,000USD-1,599,000,000USD-8,450,000,000USD
    Total Cash From Financing Activities-6,309,000,000USD-5,404,000,000USD-7,091,000,000USD-7,636,000,000USD-5,494,000,000USD-2,779,000,000USD-4,289,000,000USD-10,391,000,000USD
    Dividends Paid-4,116,000,000USD-3,836,000,000USD-3,556,000,000USD-3,309,000,000USD-3,202,000,000USD-2,560,000,000USD-2,270,000,000USD-1,974,000,000USD
    Sale Purchase Of Stock-893,000,000USD-1,295,000,000USD-1,227,000,000USD-3,795,000,000USD-2,299,000,000USD-403,000,000USD-718,000,000USD-238,000,000USD
    Change In Cash906,000,000USD720,000,000USD-2,986,000,000USD83,000,000USD2,961,000,000USD2,978,000,000USD16,000,000USD-5,563,000,000USD
    Begin Period Cash Flow7,616,000,000USD6,896,000,000USD9,882,000,000USD9,799,000,000USD6,838,000,000USD3,860,000,000USD3,844,000,000USD9,407,000,000USD
    End Period Cash Flow8,522,000,000USD7,616,000,000USD6,896,000,000USD9,882,000,000USD9,799,000,000USD6,838,000,000USD3,860,000,000USD3,844,000,000USD
    Other Cashflows From Investing Activities18,000,000USD9,000,000USD22,000,000USD70,000,000USD-27,000,000USD35,000,000USD-95,000,000USD48,000,000USD
    Other Cashflows From Financing Activities-82,000,000USD264,000,000USD167,000,000USD221,000,000USD55,000,000USD-11,000,000USD2,140,000,000USD271,000,000USD
    Unclassified Investing Cash Flow-105,000,000USD2,198,000,000USD1,988,000,000USD————48,000,000USD
    Unclassified Financing Cash Flow396,000,000USD——-800,000,000USD200,000,000USD245,000,000USD-1,842,000,000USD—
    Change To Liabilities———37,000,000USD380,000,000USD1,152,000,000USD-325,000,000USD533,000,000USD
    Cash And Cash Equivalents Changes———205,000,000USD3,031,000,000USD2,907,000,000USD32,000,000USD-5,447,000,000USD
    Unclassified Operating Cash Flow———————293,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    Continuous Glucose Monitoring Systems Sales

    Period endPeriodValueUnitSource
    2026-06-30year_to_date4,100,000,000USDDisclosure

    Diagnostic Products Remaining Performance Obligations

    Period endPeriodValueUnitSource
    2026-06-30instant6,200,000,000USDDisclosure

    Established Pharmaceuticals Remaining Performance Obligations

    Period endPeriodValueUnitSource
    2026-06-30instant243,000,000USDDisclosure

    Medical Devices Remaining Performance Obligations

    Period endPeriodValueUnitSource
    2026-06-30instant455,000,000USDDisclosure

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30GeographyInternational7,377,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyUnited States5,216,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentDiagnostic Products3,092,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentEstablished Pharmaceutical Products1,499,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentMedical Devices5,853,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentNutritional Products2,144,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyInternational6,890,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyUnited States4,274,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31SegmentDiagnostic Products2,180,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31SegmentEstablished Pharmaceutical Products1,426,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31SegmentMedical Devices5,539,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31SegmentNutritional Products2,017,000,000USDDisclosure
    Q4 2025Quarterly · 2025-12-31SegmentDiagnostic Products2,457,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentEstablished Pharmaceutical Products1,382,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentMedical Devices5,675,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentNutritional Products1,940,000,000USDLegacy provider
    FY 2025Yearly · 2025-12-31SegmentDiagnostic Products8,937,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31SegmentEstablished Pharmaceutical Products5,536,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31SegmentMedical Devices21,387,000,000USDDisclosure
    FY 2025Yearly · 2025-12-31SegmentNutritional Products8,451,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30GeographyInternational7,070,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30GeographyUnited States4,299,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30SegmentDiagnostic Products2,253,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30SegmentEstablished Pharmaceutical Products1,511,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30SegmentMedical Devices5,448,000,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30SegmentNutritional Products2,153,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30GeographyInternational6,866,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30GeographyUnited States4,276,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30SegmentDiagnostic Products2,173,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30SegmentEstablished Pharmaceutical Products1,383,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30SegmentMedical Devices5,369,000,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30SegmentNutritional Products2,212,000,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31SegmentDiagnostic Products2,520,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31SegmentEstablished Pharmaceutical Products1,268,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31SegmentMedical Devices5,052,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31SegmentNutritional Products2,129,000,000USDLegacy provider
    FY 2024Yearly · 2024-12-31SegmentDiagnostic Products9,341,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31SegmentEstablished Pharmaceutical Products5,194,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31SegmentMedical Devices18,986,000,000USDDisclosure
    FY 2024Yearly · 2024-12-31SegmentNutritional Products8,413,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30GeographyInternational6,433,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30GeographyUnited States4,202,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30SegmentDiagnostic Products2,412,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30SegmentEstablished Pharmaceutical Products1,406,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30SegmentMedical Devices4,747,000,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30SegmentNutritional Products2,066,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30GeographyInternational6,443,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30GeographyUnited States3,934,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30SegmentDiagnostic Products2,195,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30SegmentEstablished Pharmaceutical Products1,294,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30SegmentMedical Devices4,734,000,000USDDisclosure
    Q2 2024Quarterly · 2024-06-30SegmentNutritional Products2,150,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31GeographyInternational6,118,000,000USDDisclosure
    Q1 2024Quarterly · 2024-03-31GeographyUnited States3,846,000,000USDDisclosure
    FY 2023Yearly · 2023-12-31SegmentDiagnostic Products9,988,000,000USDDisclosure
    FY 2023Yearly · 2023-12-31SegmentEstablished Pharmaceutical Products5,066,000,000USDDisclosure
    FY 2023Yearly · 2023-12-31SegmentMedical Devices16,887,000,000USDDisclosure
    FY 2023Yearly · 2023-12-31SegmentNutritional Products8,154,000,000USDDisclosure
    Q3 2023Quarterly · 2023-09-30GeographyInternational6,326,000,000USDDisclosure
    Q3 2023Quarterly · 2023-09-30GeographyUnited States3,817,000,000USDDisclosure
    FY 2022Yearly · 2022-12-31SegmentDiagnostic Products16,469,000,000USDDisclosure
    FY 2022Yearly · 2022-12-31SegmentEstablished Pharmaceutical Products4,912,000,000USDDisclosure
    FY 2022Yearly · 2022-12-31SegmentMedical Devices14,802,000,000USDDisclosure
    FY 2022Yearly · 2022-12-31SegmentNutritional Products7,459,000,000USDDisclosure
    FY 2021Yearly · 2021-12-31SegmentAll Other Segments52,000,000USD0001104659-22-025141
    FY 2021Yearly · 2021-12-31SegmentDiagnostic Products15,644,000,000USD0001104659-22-025141
    FY 2021Yearly · 2021-12-31SegmentEstablished Pharmaceutical Products4,718,000,000USD0001104659-22-025141
    FY 2021Yearly · 2021-12-31SegmentMedical Devices14,367,000,000USD0001104659-22-025141
    FY 2021Yearly · 2021-12-31SegmentNutritional Products8,294,000,000USD0001104659-22-025141
    FY 2020Yearly · 2020-12-31SegmentAll Other Segments66,000,000USD0001104659-22-025141
    FY 2020Yearly · 2020-12-31SegmentDiagnostic Products10,805,000,000USD0001104659-22-025141
    FY 2020Yearly · 2020-12-31SegmentEstablished Pharmaceutical Products4,303,000,000USD0001104659-22-025141
    FY 2020Yearly · 2020-12-31SegmentMedical Devices11,787,000,000USD0001104659-22-025141
    FY 2020Yearly · 2020-12-31SegmentNutritional Products7,647,000,000USD0001104659-22-025141
    FY 2019Yearly · 2019-12-31SegmentAll Other Segments57,000,000USD0001104659-22-025141
    FY 2019Yearly · 2019-12-31SegmentDiagnostic Products7,713,000,000USD0001104659-22-025141
    FY 2019Yearly · 2019-12-31SegmentEstablished Pharmaceutical Products4,486,000,000USD0001104659-22-025141
    FY 2019Yearly · 2019-12-31SegmentMedical Devices12,239,000,000USD0001104659-22-025141
    FY 2019Yearly · 2019-12-31SegmentNutritional Products7,409,000,000USD0001104659-22-025141
    FY 2018Yearly · 2018-12-31SegmentAll Other Segments62,000,000USD0001104659-21-025751
    FY 2018Yearly · 2018-12-31SegmentDiagnostic Products7,495,000,000USD0001104659-21-025751
    FY 2018Yearly · 2018-12-31SegmentEstablished Pharmaceutical Products4,422,000,000USD0001104659-21-025751
    FY 2018Yearly · 2018-12-31SegmentMedical Devices11,370,000,000USD0001104659-21-025751
    FY 2018Yearly · 2018-12-31SegmentNutritional Products7,229,000,000USD0001104659-21-025751
    FY 2017Yearly · 2017-12-31GeographyBR541,000,000USD0001047469-18-000856
    FY 2017Yearly · 2017-12-31GeographyCanada443,000,000USD0001047469-18-000856
    FY 2017Yearly · 2017-12-31GeographyCH841,000,000USD0001047469-18-000856
    FY 2017Yearly · 2017-12-31GeographyChina2,146,000,000USD0001047469-18-000856
    FY 2017Yearly · 2017-12-31GeographyCO494,000,000USD0001047469-18-000856
    FY 2017Yearly · 2017-12-31GeographyFrance628,000,000USD0001047469-18-000856
    FY 2017Yearly · 2017-12-31GeographyGermany1,366,000,000USD0001047469-18-000856
    FY 2017Yearly · 2017-12-31GeographyIN1,237,000,000USD0001047469-18-000856
    FY 2017Yearly · 2017-12-31GeographyItaly507,000,000USD0001047469-18-000856
    FY 2017Yearly · 2017-12-31GeographyJapan1,255,000,000USD0001047469-18-000856
    FY 2017Yearly · 2017-12-31GeographyNetherlands929,000,000USD0001047469-18-000856
    FY 2017Yearly · 2017-12-31GeographyOther Countries5,741,000,000USD0001047469-18-000856
    FY 2017Yearly · 2017-12-31GeographyRU664,000,000USD0001047469-18-000856
    FY 2017Yearly · 2017-12-31GeographyUnited Kingdom498,000,000USD0001047469-18-000856
    FY 2017Yearly · 2017-12-31GeographyUnited States9,673,000,000USD0001047469-18-000856
    FY 2017Yearly · 2017-12-31GeographyVN427,000,000USD0001047469-18-000856

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.